ELUTIA INC.
ELUT · XNASCIK 1708527fmd_0PJBAFNTB23ZS3M8MPZ7MEGWGXManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 29 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 43 | 43 | 20 | 24 | 25 | 14 | 12 |
| Cost of revenue | 23 | 22 | 11 | 12 | 14 | 8 | 6 |
| Gross profit | 20 | 21 | 9 | 12 | 11 | 7 | 7 |
| Research and development | 2 | 6 | 8 | 8 | 4 | 3 | 4 |
| Selling, general and administrative | 26 | 28 | 30 | 34 | 27 | 23 | 21 |
| Total operating expenses | 28 | 34 | 38 | 47 | 42 | 37 | 34 |
| Operating income | (8) | (14) | (29) | (35) | (31) | (31) | (27) |
| Interest expense | 5 | 6 | 5 | 5 | 6 | 5 | – |
| Other non-operating income (expense) | 2 | (3) | 4 | 4 | (1) | 1 | (3) |
| Income before taxes | (12) | (22) | (30) | (36) | (41) | (45) | (16) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (12) | (22) | (30) | (36) | (41) | (45) | (16) |
| Net income | (12) | (22) | (25) | (33) | (38) | (54) | 53 |
| Net income to common shareholders | (12) | (25) | (25) | (33) | (38) | (0) | 0 |